EUR 23.6
(1.72%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 34.43 Million EUR | 4517.63% |
2022 | 6.84 Million EUR | 57.05% |
2021 | 4.36 Million EUR | 148.35% |
2020 | -9.02 Million EUR | -242.94% |
2019 | 6.31 Million EUR | -85.93% |
2018 | 44.84 Million EUR | 32.64% |
2017 | 33.81 Million EUR | 280.33% |
2016 | 8.89 Million EUR | -96.62% |
2015 | 262.88 Million EUR | 19.9% |
2014 | 219.24 Million EUR | -3.35% |
2013 | 226.84 Million EUR | 10.27% |
2012 | 205.7 Million EUR | 41.36% |
2011 | 145.52 Million EUR | 29.45% |
2010 | 112.41 Million EUR | 80.67% |
2009 | 62.21 Million EUR | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q2 | 84.15 Million EUR | 0.0% |
2023 FY | 316.3 Million EUR | 4517.63% |
2023 Q4 | 7.15 Million EUR | 0.0% |
2023 Q2 | 110.32 Thousand EUR | 0.0% |
2022 Q4 | 6.58 Million EUR | 0.0% |
2022 FY | 6.84 Million EUR | 57.05% |
2022 Q2 | 266.55 Thousand EUR | 0.0% |
2021 Q2 | 634.25 Thousand EUR | 0.0% |
2021 FY | 4.36 Million EUR | 148.35% |
2021 Q4 | 3.72 Million EUR | 0.0% |
2020 Q2 | 292.58 Thousand EUR | 0.0% |
2020 Q4 | -9.31 Million EUR | 0.0% |
2020 FY | -9.02 Million EUR | -242.94% |
2019 Q2 | -161.02 Thousand EUR | 0.0% |
2019 FY | 6.31 Million EUR | -85.93% |
2019 Q4 | 6.47 Million EUR | 0.0% |
2018 Q4 | -12.85 Million EUR | 0.0% |
2018 FY | 44.84 Million EUR | 32.64% |
2018 Q2 | 57.7 Million EUR | 0.0% |
2017 Q2 | 7.38 Million EUR | 0.0% |
2017 FY | 33.81 Million EUR | 280.33% |
2017 Q4 | 26.43 Million EUR | 0.0% |
2016 Q4 | 2.84 Million EUR | 0.0% |
2016 FY | 8.89 Million EUR | -96.62% |
2016 Q2 | 6.04 Million EUR | 0.0% |
2015 Q4 | 150.17 Million EUR | 0.0% |
2015 Q2 | 112.7 Million EUR | 0.0% |
2015 FY | 262.88 Million EUR | 19.9% |
2014 FY | 219.24 Million EUR | -3.35% |
2014 Q2 | 117.57 Million EUR | 0.0% |
2014 Q4 | 101.67 Million EUR | 0.0% |
2013 FY | 226.84 Million EUR | 10.27% |
2013 Q4 | 114.45 Million EUR | 0.0% |
2013 Q2 | 112.38 Million EUR | 0.0% |
2012 Q4 | 53.2 Million EUR | 0.0% |
2012 Q2 | 49.64 Million EUR | -0.0% |
2012 Q1 | 49.64 Million EUR | 0.0% |
2012 FY | 205.7 Million EUR | 41.36% |
2012 Q3 | 53.2 Million EUR | 7.16% |
2011 FY | 145.52 Million EUR | 29.45% |
2010 FY | 112.41 Million EUR | 80.67% |
2009 FY | 62.21 Million EUR | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Apontis Pharma AG | 36.96 Million EUR | 6.853% |
Dermapharm Holding SE | 1.13 Billion EUR | 96.967% |
Evotec SE | 781.42 Million EUR | 95.594% |
MERCK Kommanditgesellschaft auf Aktien | 20.99 Billion EUR | 99.836% |
PharmaSGP Holding SE | 101.09 Million EUR | 65.944% |
SynBiotic SE | 3.86 Million EUR | -791.669% |